A randomized trial showed that specific histological subtypes of NSCLC are very important in therapy selection and patient prognosis.39 More recently, lung AC was subdivided into clinically relevant molecular subsets based on specific driver mutations.40 Thus, the expression and function of ZNF32 in lung squamous carcinoma and other NSCLC subsets will be further examined in our next study. Here, ZNF32 is linked to non-small cell lung carcinoma.